G

GSK

Develops medicines, vaccines, and consumer health

Principal Data Engineer

Full-TimeUpdated Deadline 11/12/26
No salary listed
Expert
Bengaluru, Karnataka, India
Hybrid
Data & AnalyticsData Engineering

About the job

Requirements
  • At least 10 years of hands-on technical experience in data engineering, artificial intelligence and machine learning, and automation projects within regulated industries.
  • Proficiency in programming languages such as Python; PySpark and FastAPI are a plus.
  • Hands-on experience designing and implementing retrieval-augmented generation (RAG) architectures, context-enrichment strategies for large language model applications, vector databases such as Azure AI Search Vector Capabilities, multi-agent orchestration frameworks such as LangChain, LangGraph and Semantic Kernel, and knowledge graph integration.
  • Experience with cloud-based data platforms such as Snowflake and Azure, including development, integration and configuration of Azure Data Factory, Azure Databricks, Azure App Services, Azure Cognitive Services, ADLSv2 and Azure Key Vault.
  • Experience implementing DevOps best practices, including version control, continuous integration and continuous delivery, Azure DevOps and YAML pipelines.
  • Experience with data analytics platforms, data visualization or business intelligence tools; Power BI is preferred.
  • Experience with data virtualization using Denodo.
  • Ability to influence senior leadership and support decision-making using data and market evidence.
  • A track record of delivering business impact through process and information-technology-enabled solutions across multiple business lines.
  • Understanding of data mesh and data fabric principles.
  • Understanding of data warehouse design and extract, load and transform processes.
  • Experience designing scalable architectures and automating business processes using artificial intelligence.
  • Knowledge of cloud and web service platforms such as Azure Databricks and RESTful web services.
  • Relevant skills include application integrations, application programming interface security, cloud engineering, configuration management, database management, data engineering, data integration, data mesh, data warehouse design, front-end development, internet of things, mobile development, RESTful API design, scalable architectures, security system design, software development life cycle, version control, web development and web services.
Responsibilities
  • Design and implement end-to-end, AI-driven data pipelines that ingest, transform and analyze safety data from multiple sources.
  • Lead the development of enterprise data platforms using modern AI-native solutions, including retrieval-augmented generation, vector databases, agentic artificial intelligence, large language model operations, LangChain, LangGraph, semantic search, AI agents and Azure OpenAI.
  • Build scalable solutions that replace labor-intensive tasks with automated workflows to reduce processing time and errors.
  • Collaborate with the Product Owner and cross-functional teams to align technical solutions with the strategic product roadmap.
  • Deliver products and services that meet business strategy and requirements, and execute the product roadmap.
  • Develop approaches to extract actionable insights from complex data sets; use advanced analytics to optimize data quality, drive signal detection and support regulatory reporting.
  • Ensure solutions follow software-development best practices, including robust testing, code documentation and DevOps practices.
  • Monitor system performance, identify improvement opportunities and implement optimizations to maintain system reliability.
  • Ensure business-supporting products comply with internal security and risk-management policies and practices and external regulatory and statutory requirements, including GxP; maintain technology continuity plans for business-critical products.
  • Translate customer requests, competitive activity and industry trends into value drivers and product requirements that product teams, developers and other stakeholders can understand.
  • Consult on complex Level 3 support issues and escalations.
  • Collaborate with the broader team to deliver business value on tight timelines and adhere to the release-management calendar where applicable.
  • Work with data engineers, scientists and business stakeholders to troubleshoot issues, gather requirements and drive technical innovations.
  • Support product teams and the business in adopting agile solution-development approaches and managing change; build momentum, success stories and clear value-based versions of the vision as roadmap plans progress.
Desired Qualifications
  • PySpark and FastAPI experience.
  • Power BI experience.
  • Hands-on experience with AI-native tools and technologies.
  • A passion for delivering business outcomes, value and simplification, and for advancing science and medicines to patients.

About the company

GSK is a global healthcare company focused on three main areas: Pharmaceuticals, Vaccines, and Consumer Healthcare. It develops medicines, vaccines, and consumer health products to improve health outcomes worldwide. Its products address diseases in respiratory, HIV, oncology, and immuno-inflammatory areas; vaccines for influenza, shingles, and COVID-19; and over-the-counter wellness products. The company relies on substantial R&D and strategic partnerships to bring new products to market and to address health needs. Revenues come from sales of medicines, vaccines, and consumer health items, often complemented by patient support programs and collaborations with governments and biotech partners.

Company Size

10,001+

Company Stage

IPO

Headquarters

London, United Kingdom

Founded

1891

Get referred to GSK

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Luke Miels launched a £1.9 billion savings plan to fund R&D and late-stage development.
  • GSK expects more than £10 billion operating cash flow in 2026, financing acquisitions and launches.
  • Blenrep, Jideytro, and Excentia each have 2026-2027 catalysts that can lift revenue.

What critics are saying

  • Dresden’s 2027 closure cuts 641 jobs and exposes declining demand in legacy flu vaccines.
  • Camlipixant’s failure triggered a £1.3 billion impairment, showing pipeline execution remains fragile.
  • Zantac appeals and a securities case still threaten cash, disclosures, and management focus.

What makes GSK unique

  • GSK’s 62-asset pipeline spans HIV, oncology, vaccines, and respiratory with 20+ Phase III starts in 2026.
  • Jideytro, Blenrep, and Excentia create multiple launch vectors beyond Shingrix.
  • GSK’s vaccine and specialty-medicine manufacturing network supports global scale across regulated markets.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • 401(k) Retirement Plan
  • Remote Work Options
  • Flexible Work Hours
  • Paid Vacation
  • Paid Holidays
  • Hybrid Work Options
  • Wellness Program
  • Mental Health Support
  • Phone/Internet Stipend

Company News

Yahoo Finance
Oct 28th, 2026
GSK Q3 sales rise 5% to $11.3B as specialty medicines drive growth, 2026 guidance reaffirmed

GSK reported third-quarter sales growth of 5% at constant exchange rates to £8.9 billion, driven by specialty medicines. Core operating profit rose 5%, while core earnings per share rose 1%. The company reaffirmed its 2026 guidance, expecting sales and core operating profit in the upper half of their ranges. Higher interest costs after the $10.6 billion Nuvalent acquisition will hold core earnings per share growth in the lower half of its range. Specialty medicines grew 15%, led by Cabenuva, up 35%. Vaccines sales fell 2% on Shingrix destocking in China. Research and development spending rose 22%. GSK has started 18 phase III studies this year and expects four more. It declared a third-quarter dividend of 17 pence per share.

Yahoo Finance
Oct 28th, 2026
GSK shares slide as pipeline doubts and weak vaccine sales offset $11.3B sales beat

GSK shares fell about 4% on October 28 despite a third-quarter sales and profit beat, as investors focused on pipeline doubts and weak vaccine sales, including shingles shot Shingrix. The stock fell as much as 7.3% earlier in the day. Core profit was 54.6 pence per share on turnover of £8.89 billion, against expectations of 50.4 pence and £8.84 billion. Specialty medicines for HIV, respiratory conditions and cancer rose 15%, but sales of new asthma drug Exdensur and vaccines missed forecasts. Chief executive officer Luke Miels is running a £1.9 billion ($2.5 billion) cost-savings plan to fund drug development ahead of patent losses. Market forecasts for 2031 sales of £36.64 billion trail GSK's target of more than £40 billion. GSK kept its annual outlook and took a £328 million restructuring charge in the quarter.

Yahoo Finance
Oct 28th, 2026
FTSE 100 slips 0.3% ahead of budget as GSK falls 4.3% and Unilever drops 3.4% despite earnings beats

British stocks fell on Wednesday as investors awaited the budget and weighed results from GSK and Unilever. The FTSE 100 was down 0.30% at 08:18 GMT, extending Tuesday's fall. GSK was the top loser, down 4.3%, despite beating third-quarter expectations. Core earnings per share were 54.6 pence against a consensus of 50.4 pence, and revenue was £8.89 billion. Unilever fell 3.38% even after it raised its volume growth forecast to at least 3%. Finance Minister John Healey said he would scrap gas standing charges, which cost the typical household £108 a year. Standard Chartered raised its full-year targets after third-quarter pretax profit jumped 27% to $2.25 billion. Brent futures rose 1.4% to $110.91 a barrel.

Yahoo Finance
Oct 28th, 2026
GSK holds guidance as specialty drugs lift sales 5% to $11.3B, but $417M charge cuts profit 16%

GSK kept its 2026 guidance after specialty medicines drove another quarter of growth, though a £328 million restructuring charge cut its profit. Sales rose 5% at constant exchange rates to £8.9 billion. Core operating profit rose 5% to £3.1 billion, while total operating profit fell 16% to £2.1 billion. The charge relates to Accelerate Growth, a cost-cutting programme that targets £1.9 billion of annual savings by 2029 at a total cost of £2.4 billion. GSK plans to put the savings mainly into research and development. Specialty medicines grew 15% to £3.9 billion, while vaccines fell 2% to £2.6 billion. Net debt rose to £20.7 billion from £14.5 billion at the end of 2025, after the $10.8 billion Nuvalent takeover. Chief executive Luke Miels said GSK had "delivered another strong quarter.

Yahoo Finance
Oct 27th, 2026
GSK's oncology push: Jemperli FDA approval and strong ADC data at ESMO for $97.4B group

GSK presented late-stage oncology data at the ESMO Congress in October 2026 on three drugs: Jemperli, Mo-Rez and Ris-Rez. The £76.7 billion pharmaceuticals group is leaning on oncology as a key part of its mix. The US Food and Drug Administration (FDA) granted Jemperli accelerated approval for MSI-H/dMMR locally advanced rectal cancer. In the AZUR-1 trial, 71% of patients received dostarlimab alone, without additional treatment or progression in the assessment window. Mo-Rez showed a 62% confirmed response rate in platinum-resistant ovarian and endometrial cancers, with a median duration of 12.2 months. Ris-Rez delivered a 61% objective response rate in extensive stage small cell lung cancer. Investors should watch the phase III trials and AZUR-1 follow-up data.